Atossa Therapeutics Inc
ATOS
Market Cap$105.49M
Close$
$0.56
30.8% downside
Current Fair Value
30.8% downsideOvervalued by 30.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $105.49 Million |
|---|---|
| Enterprise Value | $34.41 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.2 |
| Beta | 1.02 |
| Outstanding Shares | 126,621,394 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.05 |
|---|---|
| PEG | -25.23 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.49 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Atossa Therapeutics Inc
CEO: Steven Quay Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.